Skip to content
Narayana Hrudayalaya logo

Narayana Hrudayalaya

NH NSE
₹1,943.70 +70.60 (+3.77%)
Market Cap
₹39,722 Cr
P/E
46.25
View as Markdown
MCP
Close 20 Nov 2026 ₹1,943.70 1Y −32.10 −1.62%
Start ₹1,975.80

Key Fundamentals

MidcapHealthcare ServicesHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
15.50%
Debt to Equity
1.21
EPS (TTM)
₹42.03
Book Value
₹244.81
Market Cap
₹39,722 Cr
P/E (TTM)
46.25
P/B
7.94
ROE
20.50%
Dividend Yield
0.24%
EBITDA
₹1,717 Cr
52W High
₹2,092.90
52W Low
₹1,589.00
Day Range
₹1,868.00 – ₹1,960.00
Volume
7,84,702

Peer Comparison

Healthcare › Healthcare Services › Hospital

Narayana Hrudayalaya peer comparison
9,200.0059.001,32,28212.470.23%21.50%17.40%27,6302,337
1,081.0076.231,05,2159.280.20%14.70%14.70%9,1461,380
702.20101.7792,3666.010.00%6.72%8.30%12,370873
779.30110.7067,9298.720.41%11.30%11.60%6,508564
825.0059.9662,2845.940.13%11.20%13.40%9,9101,061
1,480.2064.3339,7989.200.03%15.20%17.40%5,053613
Narayana Hrudayalaya (this company)
1,943.7046.2539,7227.940.24%20.50%15.50%10,273859
Median 7 companies1,081.0064.3367,9298.720.20%14.70%14.70%9,910873

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

53 Average

Data confidence 100/100

Category scores

Quality
62
Good
Returns, margins, earnings quality 22% weight
Valuation
59
Good
Cheap vs sector & own history 24% weight
Growth
99
Strong
Sales & profit trajectory 9% weight
Financial Health
17
Poor
Solvency, leverage, coverage 9% weight
Momentum
19
Poor
Trend strength, vol-adjusted 12% weight
Ownership
57
Good
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company is expected to give good quarter
  • Company has a good return on equity (ROE) track record: 3 Years ROE 24.5%

Weaknesses

1
  • Stock is trading at 7.94 times its book value

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bullish1612
OscillatorsBullish162
Moving AveragesStrong Bullish0010

Key readings

RSI (14)
63.53
Neutral
MACD (12,26,9)
35.03
Bullish
SMA (50)
1,811.53
Bullish
SMA (200)
1,841.52
Bullish

As of

Analyst Rating

Based on 10 analysts
BUY90%

9 of 10 analysts rate Buy, 1 Hold, 0 Sell.

As of

BUY
9
90%
HOLD
1
10%
SELL
0
0%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.

Revenue

Revenue growth by window
10Y+17.21%
5Y+25.04%
3Y+20.39%
1Y+44.01%
TTM+72.34%

Net profit

Net profit growth by window
10Y+44.02%
5YTurned to profit
3Y+9.91%
1Y+1.90%
TTM+1.66%

Operating cash flow

Operating cash flow growth by window
10Y+25.00%
5Y+39.76%
3Y+14.32%
1Y+64.40%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y+9.63 pp
5Y+13.46 pp
3Y−1.03 pp
1Y−2.89 pp
TTM−5.12 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹1,878 Cr
Mar 2018₹2,281 Cr
Mar 2019₹2,861 Cr
Mar 2020₹3,128 Cr
Mar 2021₹2,583 Cr
Mar 2022₹3,701 Cr
Mar 2023₹4,525 Cr
Mar 2024₹4,890 Cr
Mar 2025₹5,483 Cr
Mar 2026₹7,896 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹83.00 Cr
Mar 2018₹51.00 Cr
Mar 2019₹59.00 Cr
Mar 2020₹119 Cr
Mar 2021−₹14.00 Cr
Mar 2022₹342 Cr
Mar 2023₹607 Cr
Mar 2024₹790 Cr
Mar 2025₹791 Cr
Mar 2026₹806 Cr

Analyst Forecasts

Forecast For
Dec 26 consensus · EBITDA
₹543 Cr −10.0% vs Sep 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 17 Nov 2026
AI opinion · based on fundamentals
Risk medium

Narayana Hrudayalaya trades at ₹1,907.6 as of 2026-11-17 with a market cap of ₹38,984 Cr, a P/E of 45.39x, and a price-to-book of 7.79x. The company has delivered strong long-term revenue and profit compounding but recent TTM profit growth has moderated to 6%, while debt-to-equity stands at 1.29.

Bull Case 7
  • Compounded sales growth of 17% over 10 years and 20% over 3 years demonstrates consistent revenue expansion in a structurally growing healthcare market
  • 5-year compounded profit growth of 155% reflects a dramatic improvement in profitability and operating leverage over a meaningful period
  • ROE of 17.85% as of 2026-11-17, backed by a 3-year average ROE of 25% and 5-year average of 26%, signals strong and sustained capital efficiency
  • TTM revenue growth of 72% indicates a significant acceleration in top-line momentum in the most recent period
  • Stock price CAGR of 26% over 5 years and 19% over 10 years shows long-term wealth creation for shareholders
  • Company is expected to deliver a good upcoming quarter, suggesting near-term operational momentum remains intact
  • 10-year compounded profit growth of 42% highlights the company's ability to scale earnings over a full business cycle
Bear Case 6
  • Price-to-book ratio of 7.79x is high, meaning investors are paying a steep premium over the company's net asset value
  • Debt-to-equity ratio of 1.29 indicates meaningful leverage on the balance sheet, which increases financial risk in a rising interest rate environment
  • TTM profit growth has decelerated sharply to 6% compared to 5-year compounded profit growth of 155%, suggesting the earnings growth trajectory may be normalising
  • Dividend yield of just 0.24% offers negligible income return, making shareholders almost entirely dependent on capital appreciation
  • 1-year stock CAGR of -2% shows the stock has underperformed over the recent 12-month period despite revenue acceleration
  • ROCE of 11.39% trails ROE of 17.85%, partly reflecting the impact of debt in the capital structure and suggesting returns on total capital employed are more modest

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

22h ago

TL;DR: Narayana Hrudayalaya delivered a strong Q2FY27 with 16.5% profit growth and impressive India hospital margin expansion to 26.8%. The underlying India and Cayman businesses are performing well, with international patient revenue surging 76% and a robust 1,555-bed expansion pipeline on track. The key risk is the UK business, which is loss-making and dragging down consolidated margins to 19.5% from 24.5%. If the UK turnaround gains traction and India momentum sustains, the trend remains firmly positive heading into H2FY27.

Headwinds 3
  • UK business loss widens Oct 30

    UK revenue fell 0.9% sequentially to £64.4 million with a net loss of £2.7 million in Q2FY27, up from £2.2 million loss in Q1FY27. EBITDA margin stood at just 7.2%.

  • EBITDA margin contracts on consolidation Oct 30

    Consolidated EBITDA margin contracted to 19.5% from 24.5% YoY, largely due to the lower-margin UK business dragging down the blended figure.

  • Net debt at ₹1,883 crore Oct 30

    Net debt stood at ₹1,883 crore as of Sep 30, 2026 with a net debt-to-equity ratio of 0.38, reflecting the capital deployed for the UK acquisition and expansion projects.

Positives 6
  • Q2 profit surges 16.5% YoY Oct 30

    Consolidated net profit rose 16.5% YoY to ₹301 crore in Q2FY27, with PAT up 45.3% sequentially. Revenue surged 73% YoY to ₹2,844 crore.

  • India margins expand strongly Oct 30

    India hospital EBITDA margin expanded to 26.8% from 23.8% YoY, aided by lower doctor/nurse costs (25.9% vs 26.7%) and lower consumables (22.2% vs 23.4%).

  • International patient revenue up 76% Oct 30

    International patient revenue surged 75.7% YoY and 41.2% sequentially to ₹90.1 crore, now contributing 7% of India hospital revenue.

Neutral 4
  • NCLT approves demerger scheme Nov 4

    NCLT Bengaluru sanctioned the demerger of NH Integrated Care's clinical services into Narayana Hrudayalaya effective Apr 1, 2025. No shares were issued as consideration.

  • Investor meetings Nov 18-19 Nov 17

    Narayana Health will hold one-to-one physical meetings with institutional investors including IMCO and Wasatch Global Advisors on Nov 18-19, 2026.

  • New statutory auditors appointed Oct 30

    Board recommended B S R & Co. LLP as statutory auditors for five years from 2027 AGM, replacing Deloitte Haskins & Sells LLP.

Quarterly Results

₹ Cr
NH quarterly results, ₹ crore
Particulars Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales
1,305
1,204
1,246
1,306
1,367
1,335
1,475
1,507
1,644
2,151
2,594
2,684
2,844
Expenses
997
925
955
1,004
1,058
1,027
1,118
1,171
1,243
1,786
2,086
2,216
2,293
Operating Profit
308
279
291
302
309
307
358
337
401
365
508
468
551
OPM %
24%
23%
23%
23%
23%
23%
24%
22%
24%
17%
20%
17%
19%
Other Income
18
18
26
24
23.6
18
20
24
24
−29
25
35
51.54
Interest
23
25
28
34
35
37
41
45
42
65
91
87
96.72
Depreciation
55
63
65
61
65
70
82
84
87
122
154
156
163
PBT
248
209
226
231
232
219
254
231
297
149
288
260
343
Tax %
9%
10%
15%
13%
14%
12%
22%
15%
13%
15%
22%
20%
12%
Net Profit
227
188
191
202
199
193
197
197
258
127
224
207
301
EPS (₹)
11.09
9.20
9.33
9.85
9.72
9.44
9.65
9.62
12.64
6.20
10.96
10.14
14.73
YoY Sales growth
14
7
2
6
5
11
18
15
20
61
76
78
73

Profit & Loss

₹ Cr
NH profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
1,364
1,614
1,878
2,281
2,861
3,128
2,582
3,701
4,525
4,890
5,483
7,896
10,273
Expenses
1,236
1,434
1,642
2,064
2,566
2,694
2,394
3,038
3,538
3,722
4,185
6,255
8,380
Operating Profit
128
180
236
217
295
434
189
664
987
1,168
1,298
1,641
1,893
OPM %
9%
11%
13%
10%
10%
14%
7%
18%
22%
24%
24%
21%
18%
Other Income
6
−19
7
18.9
16.67
7
28.18
34.56
59
75.19
80
37
83
Interest
45
33
28
55
81
94
82
76
84
112
163
266
340
Depreciation
68
76
80
100
137
186
184
183
210
242
278
448
595
Exceptional Items
—
—
—
—
—
—
−6.84
−8.53
—
—
—
—
—
PBT
21
51
135
80
93
161
−56
430
752
889
936
964
1,041
Tax %
71%
59%
39%
36%
37%
26%
−75%
20%
19%
11%
16%
16%
—
Net Profit
−19
21
83
51
59
119
−14
342
607
790
791
806
859
EPS (₹)
−0.84
1.04
4.06
2.51
2.90
5.82
−0.70
16.73
29.67
38.62
38.66
39.42
42.03
Div. Payout %
0%
0%
0%
0%
35%
17%
0%
6%
8%
10%
12%
11%
—
Sales growth
25
18
16
21
25
9
−17
43
22
8
12
44
72

Balance Sheet

₹ Cr
NH balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital
200
204
204
204
204
204
204
204
204
204
204
204
204
Reserves
568
672
759
831
877
932
916
1,284
1,927
2,679
3,422
4,333
4,799
Borrowings
362
258
217
802
813
952
826
723
884
1,627
2,428
5,858
6,075
Other Liabilities
241
424
468
692
746
813
833
931
1,155
1,123
1,216
2,088
2,289
Total Liabilities
1,371
1,557
1,648
2,529
2,640
2,901
2,779
3,143
4,170
5,633
7,271
12,482
13,367
Fixed Assets
913
1,054
1,082
1,848
1,838
2,092
1,961
1,980
2,336
2,651
4,266
7,796
8,046
CWIP
20
14
53
35
56
12
20
67
259
514
86
292
328
Investments
52
87
96
9
17
86
120
132
252
844
1,084
573
1,242
Other Assets
385
402
417
637
729
711
678
964
1,323
1,624
1,835
3,822
3,752
Total Assets
1,371
1,557
1,648
2,529
2,640
2,901
2,779
3,143
4,170
5,633
7,271
12,482
13,367

Cash Flow

₹ Cr
NH cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
77
174
219
182
279
443
304
485
1,085
1,067
986
1,621
Investing
−223
−150
−146
−520
−162
−189
−113
−267
−1,176
−1,458
−1,325
−3,648
Financing
140
18
−45
315
−27
−247
−194
−159
88
488
544
2,340
Net Cash Flow
−6
42
28
−22
89
7
−2
59
−4
97
205
313
Free Cash Flow
−15
86
85
−20
129
329
235
235
563
99
−93
753
CFO/EBITDA
78
116
108
100
113
117
133
83
119
99
86
108

Ratios

NH financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
38
34
30
45
34
31
39
43
35
31
37
30
Inventory Days
56
48
45
56
48
35
32
30
31
44
40
42
Days Payable
146
152
173
200
177
177
221
180
224
214
185
248
Cash Conversion Cycle
−51
−70
−98
−100
−95
−111
−150
−108
−158
−138
−108
−176
Working Capital Days
−30
−12
−11
−10
−10
−22
−38
−16
−25
−30
−17
−19
ROCE %
7%
9%
14%
9%
9%
14%
2%
25%
32%
26%
21%
16%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Narayana Hrudayalaya insights

62 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 63.27%
  • Public 16.42%
  • DIIs 10.68%
  • FIIs 9.01%

No promoter shares pledged as of 14 Oct 2026

Change since Jun 2026

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Narayana Hrudayalaya

What does Narayana Hrudayalaya Ltd do?
Narayana Hrudayalaya Ltd is engaged in providing economical healthcare services. It has a network of multispecialty and super specialty hospitals spread across multiple locations.
Where is Narayana Hrudayalaya Ltd (NH) listed?
Narayana Hrudayalaya Ltd trades as NH on the NSE and under code 539551 on the BSE.
Which sector does Narayana Hrudayalaya Ltd belong to?
Narayana Hrudayalaya Ltd is classified under the Healthcare sector, in the Healthcare Services industry.
What is the market capitalisation of Narayana Hrudayalaya Ltd?
Narayana Hrudayalaya Ltd has a market capitalisation of ₹39,722 Cr as of 20 Nov 2026, which places it in the Midcap band.
What is the PE ratio of Narayana Hrudayalaya Ltd?
Narayana Hrudayalaya Ltd trades at a PE ratio of 46.25 as of 20 Nov 2026, on earnings per share of ₹42.03, against a book value of ₹244.81 per share.
What is the 52-week high and low of Narayana Hrudayalaya Ltd?
Over the last 52 weeks Narayana Hrudayalaya Ltd has traded between ₹1,589 and ₹2,092.9 as of 20 Nov 2026.
Does Narayana Hrudayalaya Ltd pay dividends?
Narayana Hrudayalaya Ltd has a dividend yield of 0.24%.
What is the Return on Equity (ROE) of Narayana Hrudayalaya Ltd?
Narayana Hrudayalaya Ltd reported a return on equity of 20.50%. Its debt-to-equity ratio is 1.21.

Company Information

Narayana Hrudayalaya Ltd is engaged in providing economical healthcare services. It has a network of multispecialty and super specialty hospitals spread across multiple locations.

CEO Dr. Devi Prasad Shetty M.S.
Employees 11,411
Listed 6 Jan 2016
Face Value ₹10
Shares Outstanding 20,43,60,804

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/NH.md for Narayana Hrudayalaya Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More